

Priority Issue 2

Improve Accessibilities to Medical Services

Target for
2030

- (1) Reducing burden on doctors and medical staff by utilizing IT
- (2) Development and dissemination of infectious disease diagnostic system to contribute to global health
- (3) Offering technical diagnosis training and spreading effective health practices to emerging countries

The rapid aging of society is proceeding in Japan, and population and economic growth are advancing in emerging countries. As a result, these countries are experiencing expanding medical demands, giving rise to a variety of problems, such as the insufficient number of doctors and nurses, their harsh working conditions, and regional disparities in medical services. The death rate from infectious diseases is still high in developing countries, and eradication of infectious diseases, such as AIDS, tuberculosis, and malaria, is also one of the SDGs. The Fujifilm Group is contributing to the establishment of a sound medical environment and to supporting medical staff to realize disease prevention, make early diagnoses, and provide early treatment through combining our exclusive technologies acquired over the years with the large volume of data we have accumulated in the medical IT field, and with AI technology.

Outline of
Activities
in FY2018

[Target] Expand and scale up AI & IoT technology to reduce burdens on medical staff

- In collaboration with academia, the FUJIFILM Creative AI Center, “Brain(s)” was established as a dedicated research center to foster next-generation AI technologies that can help resolve social issues, including health problems (October 2018).
- Together with Kyoto University, we have successfully developed an AI technology to support diagnosis of interstitial pneumonia*¹ (April 2019).
- Launched SYNAPSE SAI viewer, an AI diagnosis support platform, as the first product under the brand of our medical AI technology, REILI (July 2019).



“FUJIFILM Creative AI Center Brain(s)” in Marunouchi to explore next-generation AI technology as well as develop human resources in AI/ICT fields.

[Target] Market launch and scale up a novel point-of-care tuberculosis diagnostic kits in developing countries

- A highly sensitive rapid tuberculosis diagnostic kit, TB-LAM was adopted for the Phase 2 investment (FY2018 to FY2020) by the Global Health Innovative Technology (GHIT) Fund, to continue its clinical trials. TB-LAM is being developed by Fujifilm with the collaborating partner FIND*² under continuous investments from the GHIT Fund, which aims at creating innovative therapeutic drugs, vaccines, and diagnostic drugs originating in Japan to fight against infectious diseases and poverty in the developing world.

[Target] Implement a medical checkup system to help improve the medical environment in emerging countries

- Continued to carry out the FY2017 project in Brazil to promote medical collaboration in the use of remote diagnostic imaging technology funded by the Japan International Cooperation Agency (JICA) in FY2014 (completed in March 2019).
- Convened technical workshops to provide trainings to medical staff in South Africa, Myanmar, Kirghiz, etc.

*¹ Interstitial pneumonia: A general category of lung diseases in which the lungs harden through inflammation. Causes of interstitial pneumonia vary such as pneumoconiosis caused by asbestos and idiopathic interstitial pneumonia which the cause is unknown. Idiopathic interstitial pneumonia is a designated intractable disease that is difficult to treat.

*² FIND (Foundation for Innovative New Diagnostics): Swiss non-profit organization that helps development and spread new diagnostic techniques for infectious diseases suitable for developing countries.

Future
Activities
and
Targets

- Accelerate the implementation of R&D and solutions that utilize advanced medical AI Technology through the platform of “Brain(s).”
- With an aim of commercialization, additional clinical trials to be conducted for TB-LAM to further accumulate data to obtain WHO recommendation. Contribute to the SDGs Goal 3 by aligning the TB-LAM initiative with the WHO target to end the global tuberculosis epidemic by 2030.
- Scale up medical checkup systems and continue providing education and trainings to help improve the medical environment in emerging countries.

Use of AI and IoT in the Medical IT Field

The Fujifilm Group developed an AI technology that can be applied to a wide range of services, including diagnostic imaging systems, medical workflow streamlining, and medical device maintenance. In April

2018, the Fujifilm Group announced development of such widely applicable AI technologies under the brand name of REILI. To further develop this together with academia, we established the FUJIFILM Creative AI Center, Brain(s), an R&D center for next-